Drug Approval | June 12, 2022
China NMPA approves Tislelizumab for metastatic nasopharyngeal cancer
Tislelizumab is now approved in nine indications in China
Tislelizumab is now approved in nine indications in China
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
A big boost to healthcare efforts of Ayush through NARIP, CCRAS
Based on a post hoc analysis, fewer required respiratory interventions
States have an important role in ensuring food safety and healthy food practices.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
To address the preventive & primary healthcare delivery gaps in India
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Subscribe To Our Newsletter & Stay Updated
